This cohort study uses a propensity score–matched analysis to assess suicidal ideation or attempts following exposure to glucagon-like peptide 1 receptor agonists (GLP1R) in adolescents with obesity.
| # | Наименование новости | Тональность | Информативность | Дата публикации |
|---|---|---|---|---|
| 1 | Suicide Rates by Gender Among 10- to 14-Year-Olds | 0 | 9.31 | 08-09-2026 |
| 2 | Exercise and Insulin Resistance Markers in Children and Adolescents With Excess Weight | 0 | 6.08 | 01-12-2023 |
| 3 | GLP-1 weight loss and diabetes drugs linked to nutritional deficiencies in nearly 1 in 6 children | 0 | 12.56 | 24-09-2026 |
| 4 | GLP-1s Could Change More Than Your Appetite: What We Know About Their Impact on ADHD, Brain Health and Libido | 0 | 6.29 | 14-09-2026 |
| 5 | A GLP-1 has changed your life. Are you stuck taking it forever? | 0 | 7.16 | 05-09-2026 |
| 6 | STAT+: Once described as obesity medicines for ‘patients,’ GLP-1s are increasingly lifestyle drugs for ‘customers’ | 0 | 7.79 | 28-09-2026 |
| 7 | Millions more people with overweight could benefit from GLP-1 drugs to protect heart health, study suggests | 0 | 7.86 | 27-09-2026 |
| 8 | EADV: Nail Disorders Occur Frequently With GLP-1 Receptor Agonist Exposure | 0 | 11.22 | 07-10-2026 |
| 9 | Opioid Use Disorder and Evidence-Based Care Among Medicaid-Enrolled Youths | 0 | 11.83 | 02-10-2026 |